A sharp drop in hemoglobin following the start of oral anticoagulation therapy for atrial fibrillation signals a significantly heightened risk for cancer, particularly gastrointestinal and hematologic malignancies. Published in JACC: CardioOncology, new research reveals that a hemoglobin decrease of 2 g/dL or more is far from a harmless lab fluctuation. Instead, it serves as a critical clinical indicator of hidden vulnerability.
Evaluating the Korean National Health Insurance Database
The retrospective study analyzed patients with atrial fibrillation who newly began oral anticoagulation treatment between 2011 and 2020. To qualify, researchers required participants to complete two consecutive National Health Examinations within one year before and one year after starting the medication. Investigators excluded individuals with overt bleeding events, end-stage renal disease, prior malignancies, discontinued treatment before the index date, or known coagulation and platelet disorders.
Tracking Hemoglobin Shifts Across 6,789 Patients
Out of 6,789 eligible patients, 529 individuals—representing 7.8% of the cohort—experienced a hemoglobin decrease of 2 g/dL or more. The remaining 6,260 patients, accounting for 92.2% of the group, maintained stable hemoglobin levels. Baseline readings were actually higher in the decline group at 15.2 g/dL, compared to 14.2 g/dL in the stable group. Over a median follow-up of 10.6 months, hemoglobin levels plunged to a mean of 12.4 g/dL in the decline group, while holding steady at 14.3 g/dL for comparison patients.
Measuring the 1-Year Cumulative Cancer Incidence
Patients who suffered a hemoglobin drop of 2 g/dL or more faced a 1-year cumulative cancer incidence of 7.2%, with a 95% confidence interval ranging from 4.7% to 9.8%. By comparison, those without a significant drop faced a 1-year cumulative incidence of 4.0%, bounded by a 95% confidence interval of 3.4% to 4.6%.
Multivariable Cox proportional hazards models showed an adjusted hazard ratio of 1.42 for incident cancer tied to the hemoglobin reduction, backed by a 95% confidence interval of 1.10 to 1.97 and a $P$ value of .038. Incidence rates hit 6.7 per 100 person-years for the decline group against 4.3 per 100 person-years for the stable group, producing an absolute rate difference of 2.4 per 100 person-years.
Vulnerabilities in Gastrointestinal and Hematologic Cancers
Gray’s test for cumulative incidence curves pointed to specific dangers. Patients with major hemoglobin drops faced a markedly increased incidence of hematologic and gastrointestinal cancers, registering $P$ values of .003 and .011, respectively. Adjusted Cox models confirmed a significantly elevated risk specifically for gastrointestinal cancers, yielding an adjusted hazard ratio of 1.78. Hematologic cancers also tracked an elevated risk trend, though precise estimates faced limits from a low total event count. Other cancer subtypes showed no statistically significant links.
Age, Kidney Disease, and Secondary Health Risks
Subgroup analyses uncovered critical effect modifications linked to age and preexisting conditions. The connection between hemoglobin decline and adverse cancer outcomes grew stronger in patients aged 75 years or older, as well as in those diagnosed with chronic kidney disease. Taking concomitant antiplatelet therapy also intensified the observed association.
Beyond oncological diagnoses, patients with a hemoglobin reduction of 2 g/dL or more confronted a heightened risk for all-cause mortality and major bleeding events. However, the study found no significant differences between the groups regarding ischemic stroke or systemic embolism. Study authors noted limitations, including the inability to pinpoint the exact physiological causes of the hemoglobin decline and the absence of a control group without atrial fibrillation or off anticoagulation. Even so, investigators emphasized that tracking hemoglobin trends after starting therapy gives clinicians a vital window to spot hidden patient vulnerabilities.